Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG

Diabetes care1 Mar 2003Cited by 225 (Europe PMC)

PMID12610038DOI10.2337/diacare.26.3.784PepBankPUB-12610038

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, pramlintide reduced HbA1c by 0.68% at week 26, significantly more than placebo.
In plain wordsIn type 2 diabetes, pramlintide reduced HbA1c more than placebo at week 26.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c at week 26
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg BID · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change from baseline
−0.68%
pramlintide 120 microg BID, week 26
Source sentences
Summary
Treatment with pramlintide 120 micro g BID led to a sustained reduction from baseline in HbA(1c) (-0.68 and -0.62% at weeks 26 and 52, respectively), which was significantly greater than that seen with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003801
02HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, pramlintide reduced HbA1c by 0.62% at week 52, significantly more than placebo.
In plain wordsIn type 2 diabetes, pramlintide reduced HbA1c more than placebo at week 52.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c at week 52
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg BID · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c change from baseline
−0.62%
pramlintide 120 microg BID, week 52
Source sentences
Summary
Treatment with pramlintide 120 micro g BID led to a sustained reduction from baseline in HbA(1c) (-0.68 and -0.62% at weeks 26 and 52, respectively), which was significantly greater than that seen with placebo (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003802
03HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, 46% receiving pramlintide achieved HbA1c below 8%, versus 28% receiving placebo.
In plain wordsIn type 2 diabetes, more pramlintide recipients than placebo recipients achieved HbA1c below 8%.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseHbA1c below 8%
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microg BID · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Patients with HbA1c <8%
46%
pramlintide 120 microg BID, week 52
Patients with HbA1c <8%
28%
placebo, week 52
Source sentences
Summary
The proportion of patients achieving an HbA(1c) <8% was approximately twofold greater with pramlintide (120 microg BID) than with placebo (46 vs. 28%, P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003803
04HumanRandomized controlled trialEfficacy outcome
In type 2 diabetes, weight decreased by 1.4 kg with pramlintide versus a 0.7 kg gain with placebo.
In plain wordsIn type 2 diabetes, weight decreased with pramlintide and increased with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
120 microg BID · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Body weight change at week 52
−1.4 kg
pramlintide 120 microg BID
Body weight change at week 52
0.7 kg
placebo
Source sentences
Summary
The glycemic improvement with pramlintide 120 micro g BID was accompanied by a mean weight loss (-1.4 kg vs. +0.7 kg with placebo at week 52, P < 0.05) and occurred without an overall increase in the severe hypoglycemia event rate.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003804
05HumanRandomized controlled trialSafety outcome
In type 2 diabetes, pramlintide did not increase the overall severe hypoglycemia event rate.
In plain wordsIn type 2 diabetes, pramlintide did not increase the overall rate of severe low blood sugar events.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeSevere hypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
120 microg BID · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The glycemic improvement with pramlintide 120 micro g BID was accompanied by a mean weight loss (-1.4 kg vs. +0.7 kg with placebo at week 52, P < 0.05) and occurred without an overall increase in the severe hypoglycemia event rate.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003805
06HumanRandomized controlled trialSafety outcome
In type 2 diabetes, transient mild-to-moderate nausea was the most common adverse event associated with pramlintide.
In plain wordsIn type 2 diabetes, temporary mild-to-moderate nausea was the most common adverse event associated with pramlintide.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableNausea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 52 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse event associated with pramlintide use was transient, mild-to-moderate nausea.
1 context sentence(design, population, supporting numbers)
Summary · context
In a 52-week, double-blind, placebo-controlled, parallel-group, multicenter study, 656 patients with type 2 diabetes (age 57 +/- 10 years, diabetes duration 12 +/- 7 years, BMI 34.0 +/- 7.0 kg/m(2), HbA(1c) 9.1 +/- 1.2%, mean +/- SD) treated with insulin (alone or in combination with sulfonylureas a…
Report a problemFND-1261003806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.